Search
Vestipitant
go.drugbank.com/drugs/DB11949InvestigationalVestipitant has been investigated for the treatment of Tinnitus.
humanized SMART Anti-IL-12 Antibody
go.drugbank.com/drugs/DB05848ExperimentalSMART Anti-IL-12 Antibody was humanized at PDL from a murine anti-IL-12 antibody that was licensed, together with certain intellectual property related to anti-IL-12 therapy, from Hoffmann-La Roche Inc … IL-12 is a cytokine that may have considerable potential as a target in the therapy of autoimmune diseases.
NasoVAX
go.drugbank.com/drugs/DB15859InvestigationalCreated by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. … As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230).
Hyperforin
go.drugbank.com/drugs/DB01892InvestigationalNutraceuticalOne of the most important members of this family, due to its medical properties, is _Hypericum perforatum_, also known as St John's wort.
Dichlorvos
go.drugbank.com/drugs/DB11397ExperimentalVet approvedThe compound has been available on the market since 1961 and its use is a controversial topic due to environmental and health concerns. … Dichlorvos or 2,2-dichlorovinyl dimethyl phosphate is a drug of the _organophosphate_ class, frequently used as an insecticide for the control of indoor pests and for the protection of stored products
Torcetrapib
go.drugbank.com/drugs/DB06281InvestigationalTorcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination
Forasartan
go.drugbank.com/drugs/DB01342ExperimentalAs angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.
EMZ702
go.drugbank.com/drugs/DB05021InvestigationalEMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency … EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments.
Cyclopropane
go.drugbank.com/drugs/DB13984ExperimentalIts use was ultimately limited because it was highly explosive. … Cyclopropane was initially investigated because it was thought to be the toxic element in ethylene.